Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated with percutaneous coronary intervention. -insights from the SWEDEHEART registry
Authors' conclusion
In patients with AF undergoing PCI for ACS, the use of oral anticoagulants increased over time. Both a VKA- and DOAC-based strategy were associated with lower MACE and NACE, with no significant difference between the two strategies.
Study context
- Population
- Patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) undergoing PCI between 2010 and 202229% women, median age 76 years
- Participants
- 15,358 patients
- Exposure
- Vitamin K antagonist (VKA)-based and direct oral anticoagulant (DOAC)-based strategies compared with platelet inhibition (PI) only
- VKA-basedn = 4,155
- DOAC-basedn = 4,962
- PI onlyn = 6,241reference
- Outcome
- Proportion treated with oral anticoagulants
- Follow-up
- 2010 to 2021
Methodological detailsSWEDEHEART registry, Cox regression adjusted for baseline characteristics
- SWEDEHEART registry
- Cox regression adjusted for baseline characteristics
Main finding
As reported in the abstract
Proportion treated with oral anticoagulants
2010
27%
2021
82%
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| MACE (all-cause death, MI, or stroke)VKA-basedvs PI onlyAdjusted Cox regression | 0.80 (0.73–0.89) | |
| MACE (all-cause death, MI, or stroke)DOAC-basedvs PI onlyAdjusted Cox regression | 0.82 (0.74–0.90) | |
| NACE (MACE or major bleeding)VKA-basedvs PI onlyAdjusted Cox regression | 0.86 (0.78–0.94) | |
| NACE (MACE or major bleeding)DOAC-basedvs PI onlyAdjusted Cox regression | 0.85 (0.77–0.93) | |
| 0.512Adjusted hazard ratio (log scale) |
Major adverse cardiovascular events (MACE) (all-cause death, myocardial infarction (MI), or stroke)
- No difference between the two OAC strategies
Net adverse cardiovascular event (NACE) (MACE or major bleeding)
- No difference between the two OAC strategies
Original publication
Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated with percutaneous coronary intervention. -insights from the SWEDEHEART registry. Am Heart J. Published 17 November 2026. doi:10. 1016/ j. ahj. 2026. 107657
Composed by AI from the published abstract and checked against it. How Briefs are made →